Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• Ixazomib (Ninlaro) is used in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. This regimen, known as IRd, has shown significant effectiveness in prolonging progression-free survival compared to other therapies.
• The information was derived from a total of 9 studies that focused on the safety, efficacy, and specific considerations for different populations or subgroups using Ninlaro (ixazomib).
• Compared to treatments based on carfilzomib, daratumumab, and isatuximab, ixazomib's efficacy appears lower. However, its oral administration route offers convenience over some alternatives.
• Patients with certain cytogenetic abnormalities such as high-risk CAs benefit significantly from ixazomib-based therapy. Specifically, it improved outcomes for patients with t(4;14) and amp1q21 abnormalities.
• As maintenance therapy, ixazomib effectively prolonged progression-free survival but was associated with higher incidences of adverse events like grade 3-4 thrombocytopenia and neuropathy, which necessitates careful monitoring, especially in patients at risk.
• Real-world data suggests adherence to oral oncology treatments, including ixazomib, can be suboptimal due to factors like age, comorbidity, lack of social support, thus interventions are needed to improve adherence rates.